ArtemiLife's Artemisia-Infused Coffee Nears Phase 2 Completion for Prostate Cancer Maintenance Therapy
核心洞察
ArtemiLife (搜索)'s Phase 2 clinical trial investigating ArtemiCafé Decaf (搜索) as maintenance therapy for biochemical recurrence (搜索) of prostate cancer (搜索) is approaching completion at University of Kentucky's Markey Cancer Center.
The trial enrolled patients in August 2023 to evaluate whether four cups daily of the Artemisia annua-infused decaffeinated coffee over 24 weeks could stabilize rising PSA (搜索) levels in men following localized treatment.
Biochemical recurrence (搜索) affects an estimated 50-90% of men with high-risk prostate cancer (搜索) and represents a significant unmet medical need in oncology care.
ArtemiLife (搜索) announced that its Phase 2 clinical trial evaluating ArtemiCafé Decaf (搜索) as a maintenance therapy for prostate cancer (搜索) is nearing completion at the University of Kentucky's Markey Cancer Center. The trial has been investigating whether the Artemisia annua-infused decaffeinated coffee can reduce and stabilize rising prostate-specific antigen (PSA (搜索)) levels in men with biochemical recurrence (搜索) following localized prostate cancer treatment.
Addressing Critical Unmet Need
Biochemical recurrence (搜索), characterized by rising PSA (搜索) levels following surgery or radiation, affects an estimated 50-90% of men with high-risk prostate cancer (搜索) and represents one of the most challenging and underserved gaps in oncology care. The condition creates a clinical dilemma where patients face rising cancer markers but may not yet require aggressive systemic therapy.
Trial Design and Protocol
Following successful completion of Phase 1 dose escalation trials (NCT04805333), researchers designed the Phase 2 study (NCT05478239) to explore whether a daily regimen of four cups of ArtemiCafé Decaf (搜索) consumed over 24 weeks could offer patients a natural, tolerable alternative to delay or avoid more aggressive interventions. Patient enrollment commenced in August 2023.
Throughout the treatment period, researchers monitored PSA (搜索) levels, testosterone, and key biomarkers of the NRF2/KEAP1 (搜索) signaling pathway. The trial protocol represents a collaboration between ArtemiLife (搜索) and Kentucky's only NCI-designated Comprehensive Cancer Center.
Scientific Rationale
ArtemiCafé Decaf (搜索) contains a controlled dose of Artemisia annua, a plant with centuries-long history in traditional medicine and best known as the source of artemisinin, the gold standard antimalarial compound. Emerging laboratory research has revealed that artesunate, a derivative of artemisinin, exhibits meaningful anti-tumor activity, including the ability to target androgen receptor (搜索) pathways and reduce prostate cancer (搜索) cell proliferation.
Each batch of ArtemiCafé Decaf (搜索) is produced to deliver a consistent, controlled dose of Artemisia annua, using the same formulation employed in both Markey Cancer Center clinical trials.
Expanding Clinical Pipeline
ArtemiLife (搜索) outlined plans for broader clinical development following completion of the prostate cancer (搜索) trial. The company's next phase includes expanding into breast cancer (搜索) maintenance therapy, investigating applications in lung cancer (搜索), evaluating preventive applications, and scaling product development to meet growing demand.
Results from the company's ovarian cancer (搜索) Phase 1 clinical trial revealed promising safety and tolerability findings presented at the Society of Gynecologic Oncology annual meeting in Seattle in 2025, demonstrating the potential for cross-cancer applications.
Commercial Availability
In conjunction with the clinical milestone, ArtemiLife (搜索) announced completion of a new production run of ArtemiCafé Decaf (搜索), with fresh supply now available throughout the United States. The product remains the only commercially available coffee containing a controlled dose of Artemisia annua, with all plant material sourced from Kentucky farms.
"We are at a pivotal moment," said Adam Maust, CEO of ArtemiLife (搜索). "Our mission has always been to support scientific advances through a product that fits seamlessly into people's daily lives. As we conclude this prostate trial we look forward to continuing the movement that is redefining how we think about cancer maintenance, one cup at a time."
While specific trial outcomes cannot yet be disclosed, ArtemiLife (搜索) anticipates sharing results with the medical community as the study approaches its final data readout.